Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Fineline Cube Apr 28, 2026
Company

Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools

Fineline Cube Mar 27, 2024

Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China...

Company

WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions

Fineline Cube Mar 27, 2024

WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Drug

Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment

Fineline Cube Mar 27, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Alexion’s Ultomiris Secures FDA Approval for Anti-AQP4 Positive NMOSD Treatment

Fineline Cube Mar 27, 2024

AstraZeneca’s (AZ; NASDAQ: AZN) rare disease unit, Alexion, has registered its biologic Ultomiris (ravulizumab) with...

Policy / Regulatory

NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances

Fineline Cube Mar 27, 2024

The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...

Company

Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress

Fineline Cube Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline

Fineline Cube Mar 27, 2024

AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company...

Policy / Regulatory

National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023

Fineline Cube Mar 27, 2024

The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling...

Company Drug

MSD’s Winrevair Approved by FDA as First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Fineline Cube Mar 27, 2024

The US Food and Drug Administration (FDA) has granted Merck, Sharp & Dohme (MSD; NYSE:...

Policy / Regulatory

China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends

Fineline Cube Mar 27, 2024

The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs

Fineline Cube Mar 27, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released...

Company

Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending

Fineline Cube Mar 27, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting...

Company Deals

Shanghai Pharmaceuticals, SHC, and CEMCS CAS Renew Partnership to Incubate Pharmaceutical Innovations

Fineline Cube Mar 27, 2024

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...

Company Policy / Regulatory

Kobayashi Pharmaceutical Recalls Red Yeast Rice Pills in China Amid Health Concerns

Fineline Cube Mar 26, 2024

Japan-based Kobayashi Pharmaceutical has reportedly initiated a product recall in the Chinese market for its...

Company Policy / Regulatory

Surprise Resignation: Congressman Gallagher Steps Down as Biosecure Act Faces Uncertainty

Fineline Cube Mar 26, 2024

U.S. Congressman Mike Gallagher, the key proponent behind the recently introduced Biosecure Act aimed at...

Company Deals

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Deal Amid Biotech Pressures

Fineline Cube Mar 26, 2024

U.S.-based biotech Nuvation Bio Inc. (NYSE: NUVB) has announced a definitive agreement to acquire China-based...

Company Drug

FDA Grants Full Approval to AbbVie’s Elahere for Advanced Ovarian Cancer Treatment

Fineline Cube Mar 26, 2024

This week, the U.S. Food and Drug Administration (FDA) granted full approval to AbbVie’s (NYSE:...

Company Deals Hospital

Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services

Fineline Cube Mar 26, 2024

China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s...

Company Deals Drug

Biocytogen and ABL Bio Forge Partnership to Advance Bispecific ADC Development

Fineline Cube Mar 26, 2024

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South...

Company Deals

HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups

Fineline Cube Mar 26, 2024

China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science...

Posts pagination

1 … 375 376 377 … 657

Recent updates

  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
  • Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China
  • Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Others

Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.